Want to see TSE:EPRX full AI Analyst Report?
EPRX Stock Chart & Stats
C$10.20
C$0.52(6.33%)
At close: 4:00 PM EDT
C$10.20
C$0.52(6.33%)
Day’s Range― - ―
52-Week RangeC$7.15 - C$12.86
Previous CloseN/A
Volume54.38K
Average Volume (3M)59.79K
Market Cap
C$773.70M
Enterprise ValueC$469.12
Total Cash (Recent Filing)C$133.44M
Total Debt (Recent Filing)C$1.84M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Nov 11, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding65,906,630
10 Day Avg. Volume76,482
30 Day Avg. Volume59,791
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)5.04
Price to Sales (P/S)0.00
P/FCF Ratio-13.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$23.52Price Target Upside130.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.84
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Drug-delivery PlatformThe proprietary DiffuSphere platform gives Eupraxia a defined technological foundation for developing locally delivered, extended-release medicines. If its approach proves effective, sustained activity and potentially lower systemic exposure could support differentiation across multiple inflammatory treatment opportunities.
Multi-indication Development PipelineA pipeline spanning multiple inflammatory indications creates more than one route for clinical and commercial progress. Targeted corticosteroid delivery may address the company’s stated goal of sustained local activity, giving successful candidates potential relevance across several therapeutic applications.
Low Financial LeverageVery low leverage limits the burden of debt service and preserves financial flexibility relative to a more highly indebted development-stage company. The larger equity base also indicates access to equity capital, giving Eupraxia additional capacity to fund pipeline work while avoiding substantial debt exposure.
Bears Say
Pre-revenue Business ModelEupraxia currently has no reported product revenue, so its operating model has not yet demonstrated commercial demand or recurring sales generation. Until a candidate is approved and launched, the company remains dependent on clinical progress and external funding rather than internally generated operating revenue.
Widening Net LossesThe widening loss trajectory indicates that operating expenses are increasing faster than the company’s ability to generate income, consistent with continued development spending. Persistently negative profitability can accelerate capital erosion and raises the importance of successful pipeline execution over the next several quarters.
Increasing Cash Burn And Financing DependenceNegative operating and free cash flow show that reported losses are translating into substantial real cash outflows rather than being mainly non-cash accounting effects. Continued burn means Eupraxia needs financing to sustain operations until revenue begins, creating ongoing funding and dilution exposure.
Eupraxia Pharmaceuticals News
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was C$7.15 and its highest was C$12.86 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is C$773.70M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 65 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Aug 11, 2026. The company reported -C$0.307 earnings per share for the quarter, beating the consensus estimate of -C$0.312 by C$0.004.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.37.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 65,906,630 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -C$0.307 in its last earnings report, beating expectations of -C$0.312. Following the earnings report the stock price went down -2.781%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:EPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eupraxia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$23.52 (130.62% Upside)
C$23.52 (130.62% Upside)
Blogger Sentiment
Bullish
TSE:EPRX Sentiment 100%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth C$207.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
58.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
516.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an extended-release anesthetic designed for extended post-operative pain relief. Furthermore, the company is actively developing product candidates for oncology applications. Established in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals Inc. was formerly known as Plaza Capital Partners Inc. until its renaming in May 2012.
EPRX Stock 12 Month Forecast
Average Price Target
C$23.52
▲(130.62% Upside)